This is a phase I open label study designed to evaluate the safety, tolerability, PK and efficacy of selumetinib in Japanese paediatric patients with neurofibromatosis type 1 and inoperable and symptomatic plexiform neurofibroma.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety and tolerability in terms of adverse events
Timeframe: From obtaining the first informed consent until 30 days after the last dose (Selumetinib). Expected duration is approximately 2 years.